<DOC>
	<DOCNO>NCT00600366</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate efficacy biphasic insulin aspart 30 blood glucose control insulin naive type 2 diabetes fail secondary oral hypoglycaemic agent ( OHA ) .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 FlexPenÂ® Insulin Naive Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Insulin naive diabetes Current treatment OHA , secondary failure Body mass index ( BMI ) 40 kg/m2 HbA1c 8.5 % Willing able start insulin therapy perform selfblood glucose monitoring History drug alcohol abuse Receipt investigational drug within last month prior trial Known suspect allergy trial product relate product Severe uncontrolled hypertension Any disease condition , Investigator feel , would interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>